Sanofi-Aventis and UCB received FDA clearance to market once-daily Xyzal as a treatment for indoor allergies and hives in children 6 months and older as well as for outdoor allergies in those older than 2. The product already is approved for children age 6 and older.

Full Story:

Related Summaries